CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs

PartnershipPositive
AI Analysis

Summary

Vir Biotechnology entered into a licensing agreement with Gilead Sciences for cancer drugs with a potential deal value up to $1.9 billion, prompting Vir's stock to rise.

Importance:7/10
Sentiment:
0.70
licensing_dealpartnershipcancer_drugsvir_biotechnologygilead_sciences
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on October 14, 2026 1:09 PM

Read Original